CSF2 and breast carcinoma: Administration of low-dose GM-CSF in 19 patients with breast cancer, recurrent ovarian carcinoma, metastatic endometrial carcinoma, and recurrent squamous cell cancer of the cervix uteri with history of chemotherapy failure resulted in complete remission in 5% of patients and partial remission in 31.5% of patients (84).